For decades, Grifols grew rich from an empire built on blood. Founded by a plucky scientist and his two sons in the years after the Spanish Civil War, the company made a series of breakthroughs that ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

In February, the company reported positive efficacy results from a trial investigating Grifols’ fibrinogen concentrate (FC), BT524, for the treatment of acquired fibrinogen deficiency (AFD).

Grifols shares plunged by a further 14% on Wednesday following publication of another report from short seller Gotham City Research, raising additional questions about the Barcelona medicine maker ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

MADRID (Reuters) - U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Grifols’ repository of PD plasma samples is just a fraction of the more than 100 million samples the company has collected for nearly 15 years. Its proprietary bank is one of the world’s ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying ...

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma ...